Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Feb;54 Suppl 1(Suppl 1):S79-85.
doi: 10.1093/cid/cir886.

Future directions in mucormycosis research

Dimitrios P Kontoyiannis  1 , Russell E Lewis, Oliver Lortholary, Brad Spellberg, Georgios Petrikkos, Emmanuel Roilides, Ashraf Ibrahim, Thomas J Walsh
Affiliations

Future directions in mucormycosis research

Dimitrios P Kontoyiannis et al. Clin Infect Dis. 2012 Feb.

Erratum in

  • Clin Infect Dis. 2012 Apr;54(8):1220. Lotholary, Oliver [corrected to Lortholary, Oliver]
  • Clin Infect Dis. 2014 Apr;58(8):1203. Roillides, Emmanuel [corrected to Roilides, Emmanuel]

Abstract

Mucormycosis has emerged as an important opportunistic infection, especially in severely immunosuppressed hosts. The evolving epidemiology, immunopathogenesis, molecular virulence studies, early diagnosis, and pitfalls in designing clinical studies of mucormycosis are discussed in this article.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Number of articles published annually on mucormycosis since 1975 (source: SCOPUS, accessed 16 April 2010).
Figure 2.
Figure 2.
Potential study design for examining primary monotherapy for mucormycosis. Abbreviations: CR, complete response; D/C, discontinuation; IV, intravenous; LFAB, lipid formulation of amphotericin B; POSA, posaconazole; PR, partial response.
See this image and copyright information in PMC

References

    1. Neofytos D, Horn D, Anaissie E, et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis. 2009;48:265–73. - PubMed
    1. Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis. 2005;191:1350–60. - PubMed
    1. Kontoyiannis DP, Lewis RE. Agents of mucormycosis and related species. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 6th ed. Vol 2. Philadelphia, PA: Elsevier Churchill Livingstone; 2005. pp. 2973–81.
    1. Chamilos G, Luna M, Lewis RE, et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989–2003) Haematologica. 2006;91:986–9. - PubMed
    1. Chang DC, Burwell LA, Lyon GM, et al. Comparison of the use of administrative data and an active system for surveillance of invasive aspergillosis. Infect Control Hosp Epidemiol. 2008;29:25–30. - PubMed

Publication types

MeSH terms